Resistance of Helicobacter pylori to antibiotics

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue SUPPL. 1, 1997, Pages 43-53

  Megraud F ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CLARITHROMYCIN; DIRITHROMYCIN; ERYTHROMYCIN; JOSAMYCIN; METRONIDAZOLE; MIDECAMYCIN; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; RIFAMPICIN; ROKITAMYCIN; ROXITHROMYCIN; SPIRAMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CONFERENCE PAPER; DRUG RESISTANCE; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; NITROIMIDAZOLES;

EID: 0030903560     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.11.s1.11.x     Document Type: Article

References (39)

1. Organisation Mondiale de la Santé. Série de rapports techniques no. 210. Deuxième rapport du comité d'expert des antibiotiques. Genève: OMS ed, 1961, 1-25.
2. Ellner PD, Neu HC. The inhibitory quotients: a method for interpreting minimum inhibitory concentration data. J Am Med Assoc 1981; 246: 1575-8.
3. Harrison JD, Jones JA, Morris DC. Azithromycin levels in plasma and gastric tissue, juice and mucus. Eur J Clin Microbiol Infect Dis 1991; 10: 862-4.
4. Gustavson LE, Kaiser JF, Edmond AL, et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39: 2078-83.
5. Woods GL, Washington JA. Antibacterial susceptibility tests: Dilution and disk diffusion methods. In: Murray PR, Baron EJ, Pealler MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology, 6th ed. Washington: American Society for Microbiology, 1995: 1327-41.
6. Hachem CY, Versalovic J, Clarridge JE, et al. Analysis of pretreatment in vitro microbiology from a multicenter US study to evaluate eradication of Helicobacter pylori in patients with duodenal ulcers. The Third International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, 1996: 48 (Abstract).
7. Quintiliani R Jr, Courvalin P. Mechanisms of resistance to antimicrobial agents. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology, 6th ed. Washington: American Society for Microbiology, 1995: 1308-26.
8. Darmaillac V, Bouchard S, Lamouliatte H, Mégraud F. Macrolides and Helicobacter pylori, determination of MICs and effect of pH. Gastroenterology 1995; 108 (Suppl. 4): A78 (Abstract).
9. Goldman RC, Zakula D, Flamm R, Beyer J, Capobianco. Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. Antimicrob Agents Chemother 1994; 38: 1496-500.
10. Camou C, Ancelle J, Lamouliatte H, Mégraud F. E volution of the resistance of Helicobacter pylori to macrolides. The Third International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, 1996: 50 (Abstract).
11. Glupczynski Y, Goutier S, Van den Borre C, Butzler JP, Burette A. Surveillance of Helicobacter pylori resistance to antimicrobial agents in Belgium from 1989 to 1994. Gut 1995; 37 (Suppl. 1): A56 (Abstract).
12. Lopez-Brea M, Martinez MJ, Domingo D, et al. Evolution of the resistance to several antibiotics in H. pylori over a 4 year period. Gut 1995; 37 (Suppl. 1): A97 (Abstract).
13. Xia HX, Buckley M, Keane CT, O'Morain CA. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 1996; 37: 473-81.
14. Mégraud F, Camou-Juncas C, Occhialini A, Birac C. Helicobacter pylori resistance levels to clarithromycin remain stable. Gastroenterology 1996; 100: A192 (Abstract).
15. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995, 39: 577-85.
16. Sigmund CD, Ettayebi M, Morgan EA. Antibiotic resistance mutations in 16S and 23S ribosomal RNA genes of Escherichia coli. Nucleic Acids Res 1984; 12: 4653-63.
17. Doucet-Populaire F, Truffot-Pernot C, Grosset J, Jarlier V. Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. J Antimicrob Chemother 1995; 36: 129-36.
18. Lucier TS, Heitzman K, Liu SK, Hu PC. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob Agents Chemother 1995; 39: 2770-3.
19. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: 477-80.
20. Occhialini A, Urdaci M, Doucet-Populaire F, et al. Helicobacter pylori resistance to macrolides - Confirmation of point mutation and detection by PCR-RFLP. Gut 1996; 39 (Suppl. 2): A1.
21. Cayla R, Zerbib F, Talbi P, Mégraud F, Lamouliatte H. Pre and post treatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment failure. Gut 1995; 37 (Suppl. 1): A55 (Abstract).
22. Schültze K, Hentschel E, Hirschl AM. Clarithromycin or amoxicillin plus high dose ranitidine in the treatment of Helicobacter pylori positive functional dyspepsia. Eur J Gastroenterol Hepatol 1996; 8: 41-6.
23. Wurzer H, Rodrigo L, Archambault A, et al. Short-course therapy with amoxicillin-clarithromycin triple for 10 days (ACT-10) eradicates H. pylori and heals duodenal ulcer. Gut 1996; 39 (Suppl. 2): A38.
24. Glupczynski Y. European Multicentre Study Group on antibiotic susceptibility of Helicobacter pylori. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777-81.
25. Bouchard S, Birac C, Lamouliatte H, Forestier S, Mégraud F. Correlation between the MICs of metronidazole on Helicobacter pylori strains and the outcome of a lansoprazole-amoxicillin-metronidazole therapy. Gut 1996; 39 (Suppl. 2): A6.
26. Edwards DI. Nitroimidazole drugs - action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 1993; 31: 9-20.
27. Smith MA, Edwards DI. The influence of microaerophilia and anaerobiosis on metronidazole uptake in Helicobacter pylori. J Antimicrob Chemother 1995; 36: 453-61.
28. Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother 1992; 29: 115-20.
29. Smith MA, Edwards DI. Redox potential and oxygen concentration as factors in the susceptibility ofHelicobacter pylori to nitroheterocyclic drugs. J Antimicrob Chemother 1995; 35: 751-64.
30. Van Zwet AA, Thijs JC, de Graaf B. Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains. Antimicrob Agents Chemother 1995; 39: 250-2.
31. Wang Y, Roos KP, Taylor DE. Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker. J Gen Microbiol 1993; 139: 2485-93.
32. Mégraud F. H. pylori resistance to antibiotics. In: Hunt RH, Tytgat GNJ (Eds), Helicobacter pylori. Basic mechanisms to clinical cure. Amsterdam: Kluwer, 1994: 570-83.
33. Moayyedi P, Sahay P, Tompkins DS, Axon ATR. Efficacy and optimum dose of omeprazole in a new 1-week triple regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1996; 7: 835-40.
34. Buckley M, Xia HX, Hyde D, O'Morain C. Cost effective, European approach to Helicobacter pylori eradication. Gut 1995; 37 (Suppl. 2): A175 (Abstract).
35. Xia H, Keane CT, Beattie S, O'Morain CA. Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother 1994; 38: 2357-61.
36. Cederbrant G, Kahlmeter G, Ljungh A. The E test for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrob Chemother 1993; 31: 65-71.
37. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990; 34: 1637-41.
38. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995; 39: 107-11.
39. Midolo PD, Korman MG, Turnbridge JD, Lambert JR. Helicobacter pylori resistance to tetracycline. Lancet 1996; 347: 1194-5.